MétaCan
Menu
← Back to cohort
Record W4317868470 · doi:10.1136/bmjopen-2022-067640

Influence of letermovir treatment on gut inflammation in people living with HIV on antiretroviral therapy: protocol of the open-label controlled randomised CIAO study

2023· article· en· W4317868470 on OpenAlexafffundabout
Léna Royston, Stéphane Isnard, Carolina Berini, Simeng Bu, Péter L. Lakatos, Talat Bessissow, Nicolas Chomont, Marina B. Klein, Bertrand Lebouché, Alexandra de Pokomandy, Nadine Kronfli, Cecilia T. Costiniuk, Réjean Thomas, Cécile Tremblay, Guy Boivin, Jean‐Pierre Routy

Bibliographic record

VenueBMJ Open · 2023
Typearticle
Languageen
FieldMedicine
TopicCytomegalovirus and herpesvirus research
Canadian institutionsCentre Hospitalier de l’Université de MontréalMcGill University Health CentreUniversité LavalCanadian Institutes of Health Research
FundersFonds de Recherche du Québec - SantéHealth CanadaEMD SeronoMerck CanadaMcGill UniversityMcGill University Health CentreStyrelsen för Internationellt UtvecklingssamarbeteGilead SciencesCanadian HIV Trials Network, Canadian Institutes of Health ResearchViiV HealthcareSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungSanofiBristol-Myers SquibbUniversité de MontréalPfizerCanadian Institutes of Health ResearchNational Science Foundation
KeywordsMedicineAntiretroviral therapyHuman immunodeficiency virus (HIV)Protocol (science)Antiretroviral treatmentPublic healthIntensive care medicineImmunologyAlternative medicineViral loadPathology

Abstract

fetched live from OpenAlex

Introduction Chronic cytomegalovirus (CMV) infection is very frequent in people living with HIV (PLWH). High anti-CMV IgG titres, which may be linked to transient CMV replication, have been associated with earlier mortality, CD8 T-cell expansion, lower CD4/CD8 ratio and increased T-cell senescence. We previously showed that anti-CMV IgG titres correlated with gut permeability in PLWH on antiretroviral therapy (ART), which was associated with microbial translocation, systemic inflammation and non-infectious/non-AIDS comorbidities. Letermovir, a novel anti-CMV drug with a good safety profile, was recently approved for anti-CMV prophylaxis in allogeneic haematopoietic stem cell transplant recipients. A drastic and selective reduction of both low-grade replication and clinically significant CMV infections, combined with an improved immune reconstitution have been reported.In vitro, letermovir prevented CMV-induced epithelial disruption in intestinal tissues. Based on these findings, we aim to assess whether letermovir could inhibit CMV subclinical replication in CMV-seropositive PLWH receiving ART and, in turn, decrease CMV-associated gut damage and inflammation. Method and analysis We will conduct a multi-centre, open-label, randomised, controlled clinical trial, including a total of 60 CMV-seropositive ART-treated PLWH for at least 3 years, with a viral load <50 copies/mL and CD4+count >400 cells/µL. Forty participants will be randomised to receive letermovir for 14 weeks and 20 participants will receive standard of care (ART) alone. Plasma, pheripheral blood mononuclear cells (PBMCs), and stool samples will be collected. Colon biopsies will be collected in an optional substudy. We will assess the effect of letermovir on gut damage, microbial translocation, inflammation and HIV reservoir size. Ethics and dissemination The study was approved by Health Canada and the Research Ethics Boards of the McGill University Health Centre (MUHC-REB, protocol number: MP37-2022-8295). Results will be made available through publications in open access peer-reviewed journals and through the CIHR/CTN website. Trial registration number NCT05362916 .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.019
metaresearch head score (Gemma)0.013
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.035
Threshold uncertainty score0.116

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0190.013
Meta-epidemiology (narrow)0.0060.002
Meta-epidemiology (broad)0.0120.006
Bibliometrics0.0020.002
Science and technology studies0.0020.004
Scholarly communication0.0030.002
Open science0.0030.002
Research integrity0.0070.004
Insufficient payload (model declined to judge)0.0350.006

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.092
GPT teacher head0.431
Teacher spread0.339 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2023
Admission routes3
Has abstractyes

Explore more

Same venueBMJ Open→Same topicCytomegalovirus and herpesvirus research→French-language works237,207→